

**CORRIGENDUM TO THE NOTICE OF THE EXTRAORDINARY GENERAL MEETING TO BE HELD
ON WEDNESDAY, OCTOBER 23, 2024 AT 11.00 A.M.**

An Extraordinary General Meeting (“EGM”) of the Members of **INFINIUM PHARMACHEM LIMITED** (“the Company”) is scheduled to be held on **WEDNESDAY, OCTOBER 23, 2024 AT 11:00 A.M.**

The Notice of the EGM (“EGM Notice”) was dispatched to the Shareholders of the Company on 1ST OCTOBER, 2024 in due compliance with the provisions of the Companies Act, 2013, and rules made thereunder, read with circulars issued by Ministry of Corporate Affairs and Securities Exchange Board of India and all other applicable provisions. Capitalized words and expressions used but not defined herein shall have the same meaning as assigned to them in the EGM Notice.

The Company had filed applications with the stock exchange namely NSE Limited (“NSE”), for seeking in-principle approval in relation to the proposed preferential issue of Equity Shares for which the approval of the shareholders is being sought. Thereafter, the Company has received observations from NSE through e-mail dated 7TH October, 2024 and has directed the Company to rectify / provide additional details through Corrigendum. This Corrigendum is being issued to notify the amendments/ provide clarifications & additional details with respect to certain disclosures made under the explanatory statement to Item No. 1, which is annexed to the Notice (“Explanatory Statement”), as mentioned herein:

1) Clarification and amendment to Item 1 (Point 2 of “It may be noted that”) of the Explanatory Statement:

In this regard, we wish to clarify that as per the details received from the proposed allottee POOJA PRAVIN RATHI there was NIL shareholding in the Demat Account No. 12010900 05671991 and the same was confirmed by our Registrar. However, 500 shares were purchased in another Demat Account No. 12081601 43374234 and due to oversight by the proposed allottee, it was not reflected in the declaration and consequentially in our above referred Notice. Therefore, Notice shall be substituted and read as under:

“Except YASH MANOJ BAJAJ, MANOJ S BAJAJ, SHILPA PRAMOD YENGE and POOJA PRAVIN RATHI no other proposed allottees hold Equity Shares in the Company”

2) Amendment to point no. 3 - Objects of the Issue: Last para of Point no 3 “Objects of the Issue” of Notice shall be substituted and read as under

Tentatively, the funds will be utilised within 6 months from the date of receipt of funds for the Equity Shares. However, clarity regarding the actual investment and time schedule will emerge only after the actual activities have started and therefore, the issue proceeds shall be utilised in such manner as may be determined by the Board including revising the time schedule and planned expenditure/ funding requirement from time to time. However, the

Board will utilise funds within the any of the above objects mentioned only and it will be utilised in compliance with applicable Law.

3) **Amendment to point no. 4(c) - Basis on which the price has been arrived at and justification for the price (including premium, if any):** Point no 4(c) of Notice shall be substituted and read as under

c. Report of independent registered valuer: *The valuation report from registered valuer is not statutorily required for the proposed allotment of Equity Shares as there is no change in control or allotment of more than 5% to any single allottee or any allottee alongwith persons acting in concert with him/her. However, the report from registered valuer has been obtained as required by Articles of Association and for the purpose of independent assessment of the fair value and as a matter of better compliance and transparency. Accordingly, the price of Rs.246.57/- (Rupees Two Hundred Forty Six and Fifty Seven Paisa only) of Equity Shares to be issued and allotted to the proposed allottees has been determined taking into account the valuation report dated September 24, 2024 issued by Manish Santosh Buchasia, Registered Valuer (IBBI Registration No. IBBI/RV/03/2019/12235). The Valuation Report shall be available for inspection by the members and the same may be accessed on the Company's website at the link: <https://infiniumpharmachem.com/investors/investor-update>*

4) **Amendment to Point no. 16-** Identity of the natural persons who are the ultimate beneficial owners of the Equity Shares proposed to be allotted and/or who ultimately control the proposed allottees, the percentage of post Preferential Issue capital that may be held by them and change in control, if any, in the Company consequent to the Preferential Issue.

Details regarding Pooja Pravin Rathi of the Notice be substituted and read as under:

Name of the Proposed allottee	Category	Present pre-issue shareholding		Post issue shareholding*		Ultimate beneficial owners
		Pre-issue holding	% of total Equity capital	Post issue holding	% of total equity capital	
POOJA PRAVIN RATHI	Public	500	0.004	4,500	0.02	-

5) **Amendment to Point 20 - Lock-in Period:** Second point of the Notice shall be substituted and read as under:

“The entire pre-preferential allotment shareholding of the allottees, if any, shall be locked-in from the relevant date upto a period of six months from the date of trading approval as per the SEBI ICDR Regulations.”

6) Amendment to Point 21- The current and proposed status of the allottee(s) post Preferential Issue namely, promoter or non- promoter/Public.

Status of proposed allottees of Equity Shares:

Details regarding Pooja Pravin Rathi of the Notice be substituted and read as under:

Sr. No.	Name of Proposed Allottee	Current Status	Proposed Status
5	POOJA PRAVIN RATHI	Public	Public

This Corrigendum to the EGM Notice shall form an integral part of the EGM Notice, which has already been circulated to the Shareholders of the Company and on and from the date hereof, the EGM Notice shall always be read in conjunction with this Corrigendum. This Corrigendum will be made available on website of the stock exchange i.e. NSE and on the website of the Company.

All other contents of the EGM Notice, save and except as modified or supplemented by this Corrigendum, shall remain unchanged.

FOR INFINIUMPHARMACHEM LIMITED

Sanjaykumar
Viththalbhai
Patel

Digitally signed by Sanjaykumar
Viththalbhai Patel
DN: cn=Sanjaykumar Viththalbhai
Patel, c=IN, o=Capgemini, ou=Personal
email=2023.10.16.10.00.00.00.00

SANJAYKUMARVITHTHALBHAI PATEL

MANAGING DIRECTOR

DIN: 00370715

DATE: 16th October, 2024